Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
Psychedelics could potentially contribute to extending what is known as healthspan , the period of life people spend with good physical, cognitive, and social functioning. That is the central thesis of a narrative review published in 2026 by researchers at the University of British Columbia and other institutions.
The authors look beyond the possible direct biological effects of substances such as psilocybin, LSD, MDMA, and ayahuasca. They place particular emphasis on their possible effects on mental health, stress regulation, social connectedness, and health-related behavior. These factors are themselves regarded as relevant to long-term health and functional aging.
Among the possible biological interfaces, the work discusses neuroplasticity, immune and inflammatory signaling, and changes in stress physiology. At the same time, the authors stress that psychosocial improvements must not be equated with a demonstrated slowing of biological aging.
The state of the evidence is therefore decisive. The review provides no proof that psychedelics extend the human lifespan or slow the aging process. Direct effects on cognitive aging have also not been sufficiently studied so far. Observational data on possible health benefits are moreover susceptible to factors such as selection and expectancy effects, along with other methodological biases.
The authors therefore see psychedelics not as established “anti-aging agents” but as a possible starting point for researching mechanisms that could contribute to healthspan in the long term. To test this hypothesis, they call for long-term studies that link biological markers of aging with cognitive, physical, and psychosocial measures of functioning.
The safety of older and medically burdened people is of particular importance here. Classic psychedelics can temporarily raise blood pressure and heart rate, and with ibogaine there are also known risks of QT prolongation and severe cardiac arrhythmias.
Above all, the work marks out a new direction for research. The question in the foreground at present is not whether psychedelics let people live longer, but whether individual psychedelic interventions can bring about lasting changes in mental health, behavior, stress regulation, and social functioning, and whether a measurable benefit for healthy aging actually follows from that.
